Trial reportScientific reports2018
Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.
Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans.Scientific reports · 2025Pooled it
- A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.CNS drugs · 2022Pooled it
- A Systematic Review of the MDMA Model to Address Social Impairment in Autism.Current neuropharmacology · 2021Pooled it
- The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.Journal of psychopharmacology (Oxford, England) · 2022Trial
- Trial
- MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Trial
- Psilocybin modulates social behaviour in male and female mice in a time-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use.Molecular psychiatry · 2026Review
- Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats.Translational psychiatry · 2024Article
- The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects.Npj mental health research · 2024Review
- A narrative exploration of psilocybin's potential in mental health.Frontiers in psychiatry · 2024Review
- From antidepressants and psychotherapy to oxytocin, vagus nerve stimulation, ketamine and psychedelics: how established and novel treatments can improve social functioning in major depression.Frontiers in psychiatry · 2024Review
- Psilocybin's effects on cognition and creativity: A scoping review.Journal of psychopharmacology (Oxford, England) · 2023Article
- Younger adults are more prosocial than older adults in economic decision making results from the give and take game.Heliyon · 2023Article
- Dynamic modulation of inequality aversion in human interpersonal negotiations.Communications biology · 2022Article
- Optimizing the social utility of judicial punishment: An evolutionary biology and neuroscience perspective.Frontiers in human neuroscience · 2022Article
- Will psilocybin lose its magic in the clinical setting?Therapeutic advances in psychopharmacology · 2022Review
- Psychedelic Cognition-The Unreached Frontier of Psychedelic Science.Frontiers in neuroscience · 2022Review
- Foraging optimally in social neuroscience: computations and methodological considerations.Social cognitive and affective neuroscience · 2021Article
- Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.Journal of psychopharmacology (Oxford, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disruptions in social decision-making are becoming evident in many psychiatric conditions. These are studied using paradigms investigating the psychological mechanisms underlying interpersonal interactions, such as the Ultimatum Game (UG). Rejection behaviour in the UG represents altruistic punishment - the costly punishment of norm violators - but the mechanisms underlying it require clarification. To investigate the psychopharmacology of UG behaviour, we carried out two studies with healthy participants, employing serotonergic agonists: psilocybin (open-label, within-participant design, N = 19) and 3,4-methylenedioxymethamphetamine (MDMA; placebo-controlled, double-blind, crossover design, N = 20). We found that both MDMA and psilocybin reduced rejection of unfair offers (odds ratio: 0.57 and 0.42, respectively). The reduction in rejection rate following MDMA was associated with increased prosociality (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.